- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01228279
Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis (SAPD)
Effects of Non-Glucose-Based Peritoneal Dialysis Solution "EXTRANEAL" on Changes in Leptin Levels and Sympathetic Activity Induced by Conventional Glucose-Based Dialysate "DIANEAL" in Patients on Peritoneal Dialysis
Hypothesis:
Patients starting peritoneal dialysis with a glucose-based regimen have high sympathetic activity in response to an increase in leptin and insulin. Converting patients from a regimen of only glucose containing dialysate to a regimen with non-glucose-based solution, icodextrin, will reduce the insulin and leptin levels and will reverse dialysis-induced increases in sympathetic activity.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Cardiovascular mortality remains higher among patients treated with peritoneal dialysis as compared to patients treated with hemodialysis. Sympathetic hyperactivity is considered a significant emerging risk factor for cardiovascular mortality among patients with ESRD (End-Stage Renal Disease). Sympathetic activity, via its hemodynamic effects and trophic effects, and in interaction with RAAS (Renin Angiotensin Aldosterone System), does play a major role in cardiac and vascular remodelling, development of LVH and vascular hypertrophy, as well as progression to CHF. Glucose-based dialysate induces hyperinsulinemia and hyperleptinemia. We propose that hyperleptinemia induced by glucose-based peritoneal solution is a significant contributing factor to sympathetic hyperactivity in ESRD patients treated with PD, and could be prevented by non-glucose-based PD solution such as icodextrin-based.
Adult patients with ESRD starting PD as their first renal replacement therapy modality will be studied. Patients will be recruited 1-3 weeks prior to starting PD treatment. At baseline, specific studies for microneurography (MSNA), fasting plasma insulin, leptin, catecholamines and brain natriuretic peptide (BNP) will be performed. EKG will be recorded and digitized for further assessment of heart rate variability using power spectral analysis. Extracellular fluid volume status will be assessed by bioelectrical impedance. Central vascular volume will be assessed from inferior vena cava (IVC) by heart ultrasound. Consequently 24-h ambulatory blood pressure monitoring(ABPM)and a 24-h urine collection for urea clearance and creatinine clearance will be done.
All participants into the study will receive a PD treatment for 6 weeks with standard glucose-based PD solution Dianeal. The specific studies are repeated at 6 weeks.Then, patients will be randomized to one of the two groups (arms). One group will continue with Dianeal PD solution for another 12 weeks. The other group will receive Dianeal during the day and Extraneal, icodextrin or non-glucose based solution, during the night only, for the next 12 weeks. The specific studies are repeated at 12 weeks after randomization (18 weeks of PD treatment).
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
Ontario
-
Ottawa, Ontario, Canada
- Ottawa Hospital Research Institute
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Adult (age 18 years and older)
- Patients with end-stage renal disease(ESRD)/chronic kidney disease(CKD)stage 5
Exclusion Criteria:
- Diabetes Mellitus
- Acute coronary syndrome in the past 6 months
- Cardiac arrhythmias (2nd and 3rd degree heart block or premature ventricular complexes in Lown classes 4 or 5)
- Symptoms suggestive of obstructive or central sleep apnea (with a score of > 10 on Epworth sleepiness scale)
- Patients taking Clonidine
- Body mass index (BMI) > 34
- Patients unable to give consent
- Pregnant women
- Patients with leg injury involving nerve damage
- Patients taking anticoagulant medication
- Patients with significant bleeding disorder or liver disorder
- Hemoglobin <1.05 g/dl at the time of initiation of therapy
- patients with unilateral or bilateral nephrectomy
- Planned kidney transplant in the next 4 months
- Life expectancy under 6 months
- Oliguria (urine output less than 400 ml per day)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: DIANEAL
One group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with the same type of solution for another 12 weeks.
|
Weeks 1 to 6 (6 weeks):
Weeks 7 to 18 (12 weeks): *same regimen as weeks 1 to 6, for both CAPD and CCPD patients
Andere namen:
|
Actieve vergelijker: EXTRANEAL
The other group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with DIANEAL solution during the day and the non-glucose-based solution, EXTRANEAL, during the night
|
Weeks 1 to 6 (6 weeks):
Weeks 7 to 18 (12 weeks):
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Changes in muscle sympathetic nerve activity(MSNA)
Tijdsspanne: 6 weeks on PD and 18 weeks on PD
|
Muscle sympathetic nerve activity(MSNA) is measured by microneurography at
MSNA increases on a glucose-based dialysis regimen and may decrease by adding non-glucose-based solution |
6 weeks on PD and 18 weeks on PD
|
Changes in leptin levels
Tijdsspanne: 6 weeks on PD and 18 weeks on PD
|
Plasma leptin increases on a glucose-based peritoneal dialysis regimen and may decrease by adding non-glucose-based solution to the dialysis regimen
|
6 weeks on PD and 18 weeks on PD
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Changes in blood pressure as assessed from 24-hour ambulatory blood pressure monitor (ABPM)
Tijdsspanne: 6 weeks on PD and 18 weeks on PD
|
Blood pressure will be assessed with 24-hour ABPM at baseline, 6 weeks on PD and 18 weeks after starting peritoneal dilaysis.
Summary measures of each day and night period include average systolic and diastolic BP as well as % nocturnal dipping.
These summary measures can predict cardiovascular events more accurately than casual BP measures
|
6 weeks on PD and 18 weeks on PD
|
Changes in extracellular volume assessed by bioelectrical impedance (BIA)
Tijdsspanne: 6 weeks on PD and 18 weeks on PD
|
Bioelectrical impedance directly measures extracellular fluid volume and total body water.
The test is based on the ability to detect differences in the conductive properties of a cell by measuring its resistance (impedance) to electrical current.
The technique is reliable for tracking sequential changes in extracellular fluid volume.
|
6 weeks on PD and 18 weeks on PD
|
Changes in heart rate variability
Tijdsspanne: 6 weeks on PD and 18 weeks on PD
|
During the microneurography testing, EKG is recorded.
Heart rate and heart rate variability(HRV) will be analyzed from EKG data at baseline, 6 weeks and 18 weeks after starting dialysis.
|
6 weeks on PD and 18 weeks on PD
|
Changes in central intravascular volume assessed by cardiac ultrasound
Tijdsspanne: 6 weeks on PD and 18 weeks on PD
|
Central intravascular volume will be assessed by measuring inferior vena cava (IVC) diameter during cardiac ultrasound at baseline, 6 weeks and 18 weeks on dialysis treatment
|
6 weeks on PD and 18 weeks on PD
|
Changes in plasma catecholamines levels
Tijdsspanne: 6 weeks on PD and 18 weeks on PD
|
*Plasma catecholamines (epinephrine and norepinephrine) increase on a glucose-based peritoneal dialysis regimen and may decrease by adding non-glucose-based solution to the dialysis regimen
|
6 weeks on PD and 18 weeks on PD
|
Changes in BNP (Brain Natriuretic Peptide)levels
Tijdsspanne: 6 weeks on PD and 18 weeks on PD
|
*Brain Natriuretic Peptide (BNP)increases on a glucose-based peritoneal dialysis regimen and may decrease by adding non-glucose-based solution to the dialysis regimen
|
6 weeks on PD and 18 weeks on PD
|
Changes in plasma insulin levels
Tijdsspanne: 6 weeks on PD and 18 weeks on PD
|
*Plasma insulin increases on a glucose-based peritoneal dialysis regimen and may decrease by adding non-glucose-based solution to the dialysis regimen
|
6 weeks on PD and 18 weeks on PD
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Marcel Ruzicka, MD, PHD, Ottawa Hospital Research Institute
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- NA6951
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Eindstadium nierziekte (ESRD)
-
Bristol-Myers SquibbVoltooidTrombose | Nierfunctiestoornis | Factor XI | ESRD (End-Stage Renal Disease)Verenigde Staten
Klinische onderzoeken op DIANEAL
-
Baxter Healthcare CorporationVoltooidSuikerziekte | Eindstadium nierziekte (ESRD) | CAPDColombia
-
Sanford HealthGeschorstBuik, acuut | Wond Chirurgisch | Wond; BuikspierVerenigde Staten
-
Christoph AufrichtBeëindigdEindstadium nierziekteOostenrijk
-
Iperboreal Pharma SrlVoltooidInsuline-resistentie | Eindstadium nierziekteItalië
-
Yale UniversityVoltooidMogelijke toepassingen voor hartfalen | Volume-overbelastingVerenigde Staten
-
Iperboreal Pharma SrlWervingEindstadium nierziekteDenemarken, Zweden, Italië, Spanje, Verenigd Koninkrijk, Duitsland